$Addex Therapeutics(ADXN.US) surged +83% on Thursday, with trading volume over 70 times the usual average. The catalyst …
$Addex Therapeutics(ADXN.US) surged +83% on Thursday, with trading volume over 70 times the usual average.
The catalyst comes from Neurosterix, which was spun off by Addex in 2024: the latter completed a $105mn Series B financing round. Its lead pipeline candidate NTX-253 has completed Phase I trials, and the funds will be used to advance Phase II. Addex did not participate in this round but still holds an 8.5% stake, valued at approximately $18.6mn based on the current valuation.
$Addex Therapeutics(ADXN.US) has a total of only ~1.2mn ADSs outstanding; at $5.29, its market cap is under $7mn. A single equity holding in its portfolio is worth more than double that market cap, indicating the market is revaluing its private stakes. However, as non-listed equities lack liquidity and cannot be quickly converted to cash, a significant portion of the rally is driven by sentiment.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
